Navigation Links
Significant Pre-Clinical Data in Acute Lung Injury
Date:9/9/2012

The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX™. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim safety and pharmacokinetic data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence The
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
2. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
3. Patient Advocate Foundation Receives Significant Support to Aid Non-Squamous Non-Small Cell Lung Cancer Patients through the Co-Pay Relief Program
4. Cambrex Announces Significant New Supply Agreement
5. Wound Care Management Market to 2018 - Advanced Wound Care Modalities and an Expanding Patient Base Create Significant Growth Opportunities in Emerging Countries
6. Huntzinger Management Group, Inc., (HMG) Reporting Significant Growth in 2012
7. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
8. North Dakotas Stop-Sale System Achieves Significant Results In Battle Against Meth
9. Floridas Stop-Sale System Achieves Significant Results In Battle Against Meth
10. Nebraska Stop-Sale System Achieves Significant Results In Battle Against Meth
11. Texas Stop-Sale System Achieves Significant Results In Battle Against Meth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if he wants ... engaged, he should address any hearing loss he may be ... Hearing Institute (BHI) is delivering to men around the ... which leads up to and includes Father,s Day. This year, ... 16. To help men address their hearing ...
(Date:5/23/2013)... 2013 More than half of women diagnosed ... chemotherapy and still have excellent outcomes. To educate women, ... the largest sources of online consumer information about breast ... page provide recently diagnosed women with information sources, to ... "We anticipate these innovative social media campaigns ...
(Date:5/23/2013)... Mass. , May 23, 2013  Hologic, ... HOLX ), a leading developer, manufacturer and supplier ... products, with an emphasis on serving the healthcare ... large-scale observational study in a U.S. clinical practice ... technology (breast tomosynthesis) with conventional 2D mammography alone ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
(Date:5/25/2013)... 25, 2013 By working diligently for ... the integration of the 2012 Lamborghini Aventador into their ... latest entrant in the list of vehicles lined by ... is all set to thrill automobile lovers in the ... and spectacular looks, the 2012 Lamborghini Aventador comes with ...
(Date:5/25/2013)... 25, 2013 Dr. Farooq Ashraf, founder ... in Dubai, has announced his practice’s adoption of The ... only FDA-cleared femtosecond laser proven with more than 10 ... precision of LASIK. , “We are happy to announce ... Laser at our Dubai LASIK practice,” Ashraf said Thursday. ...
(Date:5/25/2013)... IBISWorld estimates that revenue for the ... rate of 28.7% to $1.0 billion in the five years ... and 2008, no new cell therapy products were introduced, according ... during that period. In the years since, however, the Food ... factor contributed to the industry's fast growth during the five ...
(Date:5/25/2013)... 2013 Ayurveda is the traditional ... or wisdom of life". While a medical science, its scope ... of consciousness. Its fundamental philosophy is that disease is the ... It believes that in order to re-establish optimal health, we ... then adopt a life style which brings us back into ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html ... of a judge's overturning of a jury's award of ... the first trial* in the country over allegations that ... to court files. , The judge in the case ... to show his cancer was caused by the medication.** ...
Breaking Medicine News(10 mins):Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 3Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 4
... ANN ARBOR, Mich. The majority of parents feel ... for their child, according to researchers at the University ... new study published in the October issue of the ... they participate in decisions made about their hospitalized childs ...
... is one of four oral medications approved by ... the treatment of alcoholism. A recent large ... the National Institute of Alcoholism and Alcohol Abuse ... a modest but significant benefit but another FDA-approved ...
... Administering hydrogen sulfide (H 2 S) directly into the ... tissue and cell damage often seen in oxygen-starved organs, ... University of Alabama at Birmingham. , H 2 S ... an unwanted side effect of restoring blood flow swiftly ...
... talking about peripheral artery disease , , WEDNESDAY, Sept. ... spent decades tickling America,s funny bone and tugging ... health she,s working for now, crisscrossing the country ... and underdiagnosed cardiovascular threat called peripheral artery disease ...
... Clarient, Inc.,(Nasdaq: CLRT ), a premier technology ... today announced,that it is scheduled to make an investor ... 4:30 p.m. EDT on Wednesday, September,26, 2007. The conference ... York City,September 24-27. A live webcast of the ...
... Dairy Commission Supports Emission Limits, Buffer Zones to Protect ... ... Board of,Supervisors decided on Tuesday to defer action on a crucial proposal ... a,Planning Commission meeting-leaving unanswered the question of whether,dairy - - related pollution ...
Cached Medicine News:Health News:Parents' participation in medical decisions linked to self-efficacy 2Health News:Family history of alcoholism affects response to drug used to treat heavy drinking 2Health News:Severe heart attack damage limited by hydrogen sulfide 2Health News:'Cosby' Star Tackles a Silent Heart Threat 2Health News:'Cosby' Star Tackles a Silent Heart Threat 3Health News:'Cosby' Star Tackles a Silent Heart Threat 4Health News:Clarient to Present at the UBS 2007 Global Life Sciences Conference 2Health News:County Board Punts to Planning Commission On Clean-Air Issue 2
... C-Peptide is devoid of any biological activity ... the structural integrity of insulin. Although insulin ... in equimolar concentrations, fasting levels of C-Peptide ... insulin owing to the longer half-life of ...
Inquire...
Measles IgG ELISA test system is designed for the qualitative detection of IgG antibodies to Measles (Rubeola) virus in human serum, and is for in vitro diagnostic use....
... Zeus Scientific, Inc. Measles test ... qualitative and quantitative detection of ... by the indirect fluorescent antibody ... determine or confirm recent infection ...
Medicine Products: